Kelly A. Hyland

Kelly A. Hyland

Auto-generated profile, based on publicly available information

Kelly A. Hyland

Duke University Medical Center

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
KHKelly A. Hyland
Kelly A. Hyland
BSBrent J. Small
Brent J. Small
JGJhanelle E. Gray
Jhanelle E. Gray
ACAlberto Chiappori
Alberto Chiappori
BCBen C. Creelan
Ben C. Creelan
PJPaul B. Jacobsen
Paul B. Jacobsen

8 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Danielle TometichDanielle Tometich
Danielle Tometich
KHKelly A. Hyland
Kelly A. Hyland
HSHatem H. Soliman
Hatem H. Soliman
HJHeather S. L. Jim
Heather S. L. Jim
LOLaura B Oswald
Laura B Oswald
Living with metastatic cancer, or metavivorship, differs from cancer survivorship and has changed as novel treatments have increased survival time. The purpose of this narrative review is to describe factors that impact challenges in metavivorship within a conceptual framework to guide future research. This review focuses on the specific metavivorship outcomes of progressive disease, survival time, symptoms, distress, financial toxicity, and quality of life. We describe the predisposing, precipitating, and perpetuating (3P) model of metavivorship. Understanding the biological, psychological, and social 3P factors that contribute to the development and maintenance of challenges in metavivorship provides a roadmap for future research. Implications of this model include prevention by targeting predisposing factors, management of precipitating factors after onset of metastatic disease, and treatment of perpetuating factors to reduce symptoms and improve quality of life during the chronic phase of metavivorship. This can be accomplished through biopsychosocial screening efforts, monitoring of patient-reported outcomes, education and communication interventions, interdisciplinary symptom management, advance care planning, and behavioral interventions to cultivate psychological resilience.

25 September 2019 in Cancer
Verified
Journal Article
Open access
PDF file
HJHeather S. L. Jim
Heather S. L. Jim
KHKelly A. Hyland
Kelly A. Hyland
ANAshley M. Nelson
Ashley M. Nelson
JPJavier Pinilla‐Ibarz
Javier Pinilla‐Ibarz
KSKendra Sweet
Kendra Sweet
HKHans Knoop
Hans Knoop
Background: Fatigue is a common and disabling side effect of targeted therapies such as tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukemia (CML). The goal of the current study was to conduct a pilot randomized trial of the first cognitive behavioral intervention developed for fatigue due to targeted therapy.Methods: Patients with CML treated with a TKI who were reporting moderate to severe fatigue were recruited and randomized 2:1 to cognitive behavioral therapy for targeted therapy–related fatigue (CBT‐TTF) delivered via FaceTime for the iPad or to a waitlist control (WLC) group. The outcomes were acceptability, feasibility, and preliminary efficacy for fatigue (Functional Assessment of Chronic Illness Therapy–Fatigue; primary outcome) and quality of life (Functional Assessment of Cancer Therapy–General; secondary outcome). Participants were assessed before randomization and after treatment (ie, approximately 18 weeks later).Results: A total of 44 patients (mean age, 55 years; 48% female) were assigned to CBT‐TTF (n = 29) or WLC (n = 15). The study participation rate was 59%. Among the patients assigned to CBT‐TTF, 79% completed the intervention. Intent‐to‐treat analyses indicated that patients assigned to CBT‐TTF demonstrated greater improvements in fatigue (d = 1.06; P < .001) and overall quality of life (d = 1.15; P = .005) than those assigned to WLC. More patients randomized to CBT‐TTF than WLC demonstrated clinically significant improvements in fatigue (85% vs 29%) and quality of life (88% vs 54%; P values ≤ .016).Conclusions: CBT‐TTF displays preliminary efficacy in improving fatigue and quality of life among fatigued patients with CML treated with TKIs. The findings suggest that a larger randomized study is warranted.

28 February 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
AHAasha I. Hoogland
Aasha I. Hoogland
RJReena V. Jayani
Reena V. Jayani
ACAaron Collier
Aaron Collier
NINathaly Irizarry‐Arroyo
Nathaly Irizarry‐Arroyo
YRYvelise Rodriguez
Yvelise Rodriguez
HJHeather S. L. Jim
Heather S. L. Jim
Chimeric antigen receptor T‐cell therapy with axicabtagene ciloleucel (axi‐cel) has considerably improved survival in adults with relapsed/refractory large B‐cell lymphoma. This study reports patient‐reported outcomes (PROs) such as quality of life (QOL) and toxicity in the first 90 days after treatment. Hematologic cancer patients treated with axi‐cel (N = 103, mean age = 61, 39% female) completed SF‐36 or PROMIS‐29 QOL questionnaires prior to treatment and 90 days after. PRO‐Common Terminology Criteria for Adverse Events toxicity items were completed by patients at baseline and 14, 30, 60, and 90 days after treatment. Mixed models examined change in PROs over time. From preinfusion to 90 days later, patients reported improvements in physical functioning, pain, and fatigue (ps < 0.01), but worsening of anxiety (p = 0.02). Patient‐reported toxicities worsened by day 14 with improvement thereafter. The five most severe symptoms at day 14 included fatigue, decreased appetite, dry mouth, diarrhea frequency, and problems with concentration. Results indicate improvement in some domains of QOL over time with transient patient‐reported toxicities.

17 June 2020 in Psycho-Oncology
Verified
Journal Article
Open access
PDF file
KHKelly A. Hyland
Kelly A. Hyland
HJHeather S.L. Jim
Heather S.L. Jim
Click on the article title to read more.

10 June 2020 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
JPJulie M. Cessna Palas
Julie M. Cessna Palas
KHKelly A. Hyland
Kelly A. Hyland
ANAshley M. Nelson
Ashley M. Nelson
BSBrent J. Small
Brent J. Small
HJHeather S. L. Jim
Heather S. L. Jim
PJPaul B. Jacobsen
Paul B. Jacobsen